ANDA 205439, held by Huaren Pharmaceutical Co Ltd. Hydrochlorothiazide; Valsartan.
As of Nov 16, 2026, ANDA 205439 (Hydrochlorothiazide; Valsartan), held by Huaren Pharmaceutical Co Ltd, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 6, 2017 | Original application | Tentative approval | None posted |
| Hydrochlorothiazide; Valsartan12.5MG;160MG · tablet;oral | Hydrochlorothiazide; Valsartan | None (tentative approval) |
| Hydrochlorothiazide; Valsartan25MG;160MG · tablet;oral | Hydrochlorothiazide; Valsartan | None (tentative approval) |
| Hydrochlorothiazide; Valsartan12.5MG;320MG · tablet;oral | Hydrochlorothiazide; Valsartan | None (tentative approval) |
| Hydrochlorothiazide; Valsartan25MG;320MG · tablet;oral | Hydrochlorothiazide; Valsartan | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters